Omolola Eniola Adefeso

Dr. Omolola Eniola Adefeso

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYun Chang
Yun Chang
XCXuechao Cai
Xuechao Cai
RSRamizah Syahirah
Ramizah Syahirah
YYYuxing Yao
Yuxing Yao
YXYang Xu
Yang Xu
XBXiaoping Bao
Xiaoping Bao
Glioblastoma (GBM) is one of the most aggressive and lethal solid tumors in human. While efficacious therapeutics, such as emerging chimeric antigen receptor (CAR)-T cells and chemotherapeutics, have been developed to treat various cancers, their effectiveness in GBM treatment has been hindered largely by the blood-brain barrier and blood-brain-tumor barriers. Human neutrophils effectively cross physiological barriers and display effector immunity against pathogens but the short lifespan and resistance to genome editing of primary neutrophils have limited their broad application in immunotherapy. Here we genetically engineer human pluripotent stem cells with CRISPR/Cas9-mediated gene knock-in to express various anti-GBM CAR constructs with T-specific CD3ζ or neutrophil-specific γ-signaling domains. CAR-neutrophils with the best anti-tumor activity are produced to specifically and noninvasively deliver and release tumor microenvironment-responsive nanodrugs to target GBM without the need to induce additional inflammation at the tumor sites. This combinatory chemo-immunotherapy exhibits superior and specific anti-GBM activities, reduces off-target drug delivery and prolongs lifespan in female tumor-bearing mice. Together, this biomimetic CAR-neutrophil drug delivery system is a safe, potent and versatile platform for treating GBM and possibly other devastating diseases.

1 February 2010 in Biomaterials
Verified
Journal Article
Closed access
PCPhapanin Charoenphol
Phapanin Charoenphol
RHRyan B. Huang
Ryan B. Huang
OAOmolola Eniola Adefeso
Omolola Eniola Adefeso

1 February 2021 in Cell
Verified
Journal Article
Closed access
KSKelly R. Stevens
Kelly R. Stevens
KMKristyn S. Masters
Kristyn S. Masters
PIP.I. Imoukhuede
P.I. Imoukhuede
KHKarmella A. Haynes
Karmella A. Haynes
LSLori A. Setton
Lori A. Setton
OAOmolola Eniola Adefeso
Omolola Eniola Adefeso

8 February 2013 in Langmuir
Verified
Journal Article
Closed access
KNKatawut Namdee
Katawut Namdee
ATAlex J. Thompson
Alex J. Thompson
PCPhapanin Charoenphol
Phapanin Charoenphol
OAOmolola Eniola Adefeso
Omolola Eniola Adefeso

1 July 2013 in Biomaterials
Verified
Journal Article
Closed access
ATAlex J. Thompson
Alex J. Thompson
EMEric M. Mastria
Eric M. Mastria
OAOmolola Eniola Adefeso
Omolola Eniola Adefeso

15 January 2022 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
VSViolet V. Sheffey
Violet V. Sheffey
ESEmily B. Siew
Emily B. Siew
ETEden E. L. Tanner
Eden E. L. Tanner
OAOmolola Eniola Adefeso
Omolola Eniola Adefeso
Numerous human disorders can benefit from targeted, intravenous (IV) drug delivery. Polymeric nanoparticles have been designed to undergo systemic circulation and deliver their therapeutic cargo to target sites in a controlled manner. Poly(lactic‐co‐glycolic) acid (PLGA) is a particularly promising biomaterial for designing intravenous drug carriers due to its biocompatibility, biodegradability, and history of clinical success across other routes of administration. Despite these merits, PLGA remains markedly absent in clinically approved IV drug delivery formulations. A prominent factor in PLGA particles' inability to succeed intravenously may lie in the hydrophobic character of the polyester, leading to the adsorption of serum proteins (i.e., opsonization) and a cascade of events that end in their premature clearance from the bloodstream. PEGylation, or surface‐attached polyethylene glycol chains, is a common strategy for shielding particles from opsonization. Polyethylene glycol (PEG) continues to be regarded as the ultimate “stealth” solution despite the lack of clinical progress of PEGylated PLGA carriers. This review reflects on some of the reasons for the clinical failure of PLGA, particularly the drawbacks of PEGylation, and highlights alternative surface coatings on PLGA particles. Ultimately, a new approach will be needed to harness the potential of PLGA nanoparticles and allow their widespread clinical adoption.